IN VITRO, NILUTAMIDE HAS BEEN SHOWN TO INHIBIT THE ACTIVITY OF LIVER CYTOCHROME P-450 ISOENZYMES AND, THEREFORE, MAY REDUCE THE METABOLISM OF COMPOUNDS REQUIRING THESE SYSTEMS.
CONSEQUENTLY, DRUGS WITH A LOW THERAPEUTIC MARGIN, SUCH AS VITAMIN K ANTAGONISTS, PHENYTOIN, AND THEOPHYLLINE, COULD HAVE A DELAYED ELIMINATION AND INCREASES IN THEIR SERUM HALF-LIFE LEADING TO A TOXIC LEVEL.